Non-contraceptive estrogen products draft guidance
Executive Summary
Comment period for draft "Labeling Guidance for Non-Contraceptive Estrogen Drug Products" is reopened by FDA. Comments may be submitted until Feb. 13. The draft guidance was published in the Federal Register Oct. 15